New ATA Guidelines Support Minimally Invasive Options for Patients with Differentiated Thyroid Cancer
2025 American Thyroid Association Recommendations Highlight Active Surveillance, Percutaneous Ablation, and Tailored Surgical and Long-Term Management Approaches
The American Thyroid Association (ATA) has issued its 2025 Management Guidelines for Adult Patients with Differentiated Thyroid Cancer (DTC), underscoring an evidence-based shift toward more individualized, less invasive approaches to thyroid cancer care. The guidelines acknowledge the role of active surveillance and percutaneous ablation in select patients, emphasize tailored surgical strategies, refine the use of radioactive iodine (RAI), and highlight survivorship and long-term quality-of-life concerns.
These guidelines were developed by a multidisciplinary task force of endocrinologists, surgeons, oncologists, radiologists, pathologists, and patient advocates. They provide clinicians and patients with updated recommendations across the thyroid cancer journey, from diagnosis and treatment to survivorship.
Active Surveillance and Percutaneous Ablation for Select Patients
For the first time, the ATA guidelines explicitly recognize active surveillance and percutaneous ablation as appropriate management options for certain low-risk patients with DTC (Recommendation 11). These approaches are particularly valuable for individuals with small, intrathyroidal, low-risk tumors, offering an alternative to upfront surgery while minimizing overtreatment.
Percutaneous ablation techniques, including radiofrequency ablation (RFA) have demonstrated favorable outcomes in local tumor control and patient safety, aligning with the guideline’s emphasis on balancing benefit and risk in individualized care strategies.
Surgical Approaches Refined
The guidelines reaffirm the importance of surgical expertise in reducing complication rates and provide refined recommendations on the extent of thyroidectomy, lymph node dissection, and perioperative care. Updates address when completion thyroidectomy should be performed, the management of recurrent laryngeal nerves, and strategies to safeguard parathyroid function.
These refinements aim to improve patient safety, reduce complications such as hypocalcemia or vocal cord dysfunction, and ensure that surgical intervention is deployed only where it is clinically justified.
Radioactive Iodine Therapy: More Selective Use
While RAI remains an essential therapy for certain intermediate- and high-risk patients, the 2025 guidelines call for a more selective and evidence-based application of RAI. Routine use in low-risk patients is discouraged, reflecting the shift toward minimizing unnecessary exposure and side effects, including salivary gland and reproductive concerns.
The guidelines also provide updated protocols for preparing patients for RAI, radiation safety education, and management of potential side effects.
Long-Term Management and Survivorship
The ATA places new emphasis on tailored long-term management, introducing a refined framework for TSH suppression based on recurrence risk, and allowing for de-escalation of monitoring in patients with low-risk disease and excellent response to therapy.
The guidelines also highlight the importance of quality-of-life considerations, including psychosocial support, financial hardship (financial toxicity), and survivorship planning such as ensuring care goes beyond initial treatment to encompass the full patient journey.
Expert Perspective
The 2025 ATA Guidelines represent an important step forward in thyroid cancer management, particularly with the cautious inclusion of radiofrequency ablation (RFA) for selected cases. For the first time, the ATA acknowledges RFA as a potential alternative to surgery or active surveillance in well-selected patients with low-risk papillary thyroid microcarcinoma (PTMC), as well as in some cases of recurrent thyroid cancer.
It is important to note, however, that the guidelines emphasize RFA should be applied with caution. The decision to proceed with ablation requires careful communication between physicians and patients, ensuring that choices are made through shared decision-making.
Thermal ablation, including RFA, is not intended to replace established treatments such as surgery, but rather to serve as a complementary or alternative option in specific, well-defined clinical situations.
About Differentiated Thyroid Cancer
Differentiated thyroid cancer (DTC) including papillary, follicular, and oncocytic carcinomas account for more than 90% of all thyroid cancers. In the United States alone, an estimated 44,020 new thyroid cancer cases were diagnosed in 2024. Prognosis is generally excellent, but recurrence rates range from 15–35%, and management decisions must be carefully balanced to avoid overtreatment while ensuring long-term disease control.
See the full guidelines HERE
New ATA Guidelines Support Minimally Invasive Options for Patients with Differentiated Thyroid Cancer
2025 American Thyroid Association Recommendations Highlight Active Surveillance, Percutaneous Ablation, and Tailored Surgical and Long-Term Management Approaches
The American Thyroid Association (ATA) has issued its 2025 Management Guidelines for Adult Patients with Differentiated Thyroid Cancer (DTC), underscoring an evidence-based shift toward more individualized, less invasive approaches to thyroid cancer care. The guidelines acknowledge the role of active surveillance and percutaneous ablation in select patients, emphasize tailored surgical strategies, refine the use of radioactive iodine (RAI), and highlight survivorship and long-term quality-of-life concerns.
These guidelines were developed by a multidisciplinary task force of endocrinologists, surgeons, oncologists, radiologists, pathologists, and patient advocates. They provide clinicians and patients with updated recommendations across the thyroid cancer journey, from diagnosis and treatment to survivorship.
Active Surveillance and Percutaneous Ablation for Select Patients
For the first time, the ATA guidelines explicitly recognize active surveillance and percutaneous ablation as appropriate management options for certain low-risk patients with DTC (Recommendation 11). These approaches are particularly valuable for individuals with small, intrathyroidal, low-risk tumors, offering an alternative to upfront surgery while minimizing overtreatment.
Percutaneous ablation techniques, including radiofrequency ablation (RFA) have demonstrated favorable outcomes in local tumor control and patient safety, aligning with the guideline’s emphasis on balancing benefit and risk in individualized care strategies.
Surgical Approaches Refined
The guidelines reaffirm the importance of surgical expertise in reducing complication rates and provide refined recommendations on the extent of thyroidectomy, lymph node dissection, and perioperative care. Updates address when completion thyroidectomy should be performed, the management of recurrent laryngeal nerves, and strategies to safeguard parathyroid function.
These refinements aim to improve patient safety, reduce complications such as hypocalcemia or vocal cord dysfunction, and ensure that surgical intervention is deployed only where it is clinically justified.
Radioactive Iodine Therapy: More Selective Use
While RAI remains an essential therapy for certain intermediate- and high-risk patients, the 2025 guidelines call for a more selective and evidence-based application of RAI. Routine use in low-risk patients is discouraged, reflecting the shift toward minimizing unnecessary exposure and side effects, including salivary gland and reproductive concerns.
The guidelines also provide updated protocols for preparing patients for RAI, radiation safety education, and management of potential side effects.
Long-Term Management and Survivorship
The ATA places new emphasis on tailored long-term management, introducing a refined framework for TSH suppression based on recurrence risk, and allowing for de-escalation of monitoring in patients with low-risk disease and excellent response to therapy.
The guidelines also highlight the importance of quality-of-life considerations, including psychosocial support, financial hardship (financial toxicity), and survivorship planning such as ensuring care goes beyond initial treatment to encompass the full patient journey.
Expert Perspective
The 2025 ATA Guidelines represent an important step forward in thyroid cancer management, particularly with the cautious inclusion of radiofrequency ablation (RFA) for selected cases. For the first time, the ATA acknowledges RFA as a potential alternative to surgery or active surveillance in well-selected patients with low-risk papillary thyroid microcarcinoma (PTMC), as well as in some cases of recurrent thyroid cancer.
It is important to note, however, that the guidelines emphasize RFA should be applied with caution. The decision to proceed with ablation requires careful communication between physicians and patients, ensuring that choices are made through shared decision-making.
Thermal ablation, including RFA, is not intended to replace established treatments such as surgery, but rather to serve as a complementary or alternative option in specific, well-defined clinical situations.
About Differentiated Thyroid Cancer
Differentiated thyroid cancer (DTC) including papillary, follicular, and oncocytic carcinomas account for more than 90% of all thyroid cancers. In the United States alone, an estimated 44,020 new thyroid cancer cases were diagnosed in 2024. Prognosis is generally excellent, but recurrence rates range from 15–35%, and management decisions must be carefully balanced to avoid overtreatment while ensuring long-term disease control.
See the full guidelines HERE